J B Chem In Marketing Pact With Austrian Firm
JB Chemicals & Pharmaceuticals (JBPL), the Rs 190 crore-pharma firm has entered into a technical collaboration with Fresenins GMBH of Austria for marketing some of its speciality products. J B Mody, chairman and managing director, JBPL, said the special products were for chronic constipation, prehepatic and hepatic coma.
In the current year, JBPL has introduced a new anti-oxidant and various therapeutic products such as vagititis, gingivitis and perodontitis. It has also launched some new products for pelvic inflammatory diseases and an anti- diarrhea formulation.
JBPL, a few months back, was granted a product patent by the US Patents and Trade Marks office for the controlled release formulations of Ranitidine. Currently, the market for this product in US is expected to be over $3 billion.
Similarly the company has also been granted product patents in South Africa for Ranitidine and Nifedipine. In the first quarter ended June 30, 1998, JBPL declared a 28.46 per cent jump in net profit to Rs 5.10 crore as against Rs 3.97 crore in the corresponding period last year. While sales during the quarter increased by 8 per cent to Rs 41.30 crore as against Rs 37.51 crore last year.
JBPL commissioned its project to manufacture injectables and tablets at Panoli, Gujarat, in April, 1998. The project complies to US FDA standards.
In the fiscal 1997-98, JBPL has issued bonus shares in the ratio of 1:1.